We are live on ! Find out more
PA

PharVision Advisers Portfolio holdings

AUM $9.86M
1-Year Est. Return 9.93%
This Fund
S&P 500
This Quarter Est. Return
-7.09%
1 Year Est. Return
+9.93%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$9.86M
AUM Growth
-$188M
Cap. Flow
-$186M
Cap. Flow %
-1,882.29%
Top 10 Hldgs %
17.98%
Holding
708
New
41
Increased
5
Reduced
51
Closed
611

Top Buys

Rank Stock Value
1
ACVA icon
ACV Auctions
ACVA
+$194K
2
RPD icon
Rapid7
RPD
+$183K
3
EFC
Ellington Financial
EFC
+$181K
4
SAN icon
Banco Santander
SAN
+$159K
5
OSCR icon
Oscar Health
OSCR
+$155K

Top Sells

Rank Stock Value
1
EXLS icon
EXL Service
EXLS
+$830K
2
DK icon
Delek US
DK
+$724K
3
AVGO icon
Broadcom
AVGO
+$669K
4
ITRI icon
Itron
ITRI
+$666K
5
EAT icon
Brinker International
EAT
+$649K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 17.83%
2 Technology 15.87%
3 Healthcare 10.98%
4 Industrials 10.86%
5 Real Estate 9.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BTG icon
26
B2Gold
BTG
$4.86B
$127K 1.29%
28,064
-40,223
-59% -$202K
ITUB icon
27
Itaú Unibanco
ITUB
$91.7B
$127K 1.29%
15,149
-8,107
-35% -$67.8K
OSCR icon
28
Oscar Health
OSCR
$8.92B
$126K 1.28%
+10,998
New +$155K
ACVA icon
29
ACV Auctions
ACVA
$1.29B
$125K 1.27%
+29,579
New +$194K
HLN icon
30
Haleon
HLN
$44.2B
$123K 1.25%
+12,303
New +$128K
MTA
31
Metalla Royalty & Streaming
MTA
$675M
$122K 1.23%
+18,345
New +$145K
BORR
32
Borr Drilling
BORR
$1.24B
$121K 1.23%
+20,978
New +$107K
ASAN icon
33
Asana
ASAN
$1.75B
$120K 1.22%
18,741
-30,450
-62% -$268K
GO icon
34
Grocery Outlet
GO
$918M
$119K 1.21%
+16,876
New +$147K
TRTX
35
TPG RE Finance Trust
TRTX
$670M
$117K 1.18%
+14,932
New +$129K
TROX icon
36
Tronox
TROX
$949M
$113K 1.15%
+11,616
New +$80.5K
PANL icon
37
Pangaea Logistics
PANL
$469M
$113K 1.15%
16,015
-17,233
-52% -$136K
TKC icon
38
Turkcell
TKC
$5.07B
$113K 1.15%
18,783
+299
+2% +$1.9K
BTDR icon
39
Bitdeer Technologies
BTDR
$2.77B
$112K 1.14%
+12,951
New +$136K
GOGO icon
40
Gogo Inc
GOGO
$475M
$111K 1.13%
27,669
-43,773
-61% -$199K
UWMC icon
41
UWM Holdings
UWMC
$641M
$111K 1.12%
30,619
-71,313
-70% -$328K
RPD icon
42
Rapid7
RPD
$799M
$109K 1.11%
+19,872
New +$183K
SNAP icon
43
Snap
SNAP
$7.67B
$109K 1.11%
23,753
-15,009
-39% -$88.4K
KODK icon
44
Kodak
KODK
$750M
$106K 1.08%
11,743
-21,268
-64% -$162K
ARCO icon
45
Arcos Dorados Holdings
ARCO
$1.72B
$105K 1.07%
12,735
-29,095
-70% -$236K
AVPT icon
46
AvePoint
AVPT
$2.81B
$102K 1.04%
10,733
-7,055
-40% -$79.5K
PHR icon
47
Phreesia
PHR
$660M
$99.2K 1.01%
11,833
-9,803
-45% -$130K
HIMX
48
Himax Technologies
HIMX
$2.21B
$98.2K 1%
+12,474
New +$102K
NIO icon
49
NIO
NIO
$12.1B
$98K 0.99%
16,259
-94,285
-85% -$476K
ILPT
50
Industrial Logistics Properties Trust
ILPT
$572M
$97.8K 0.99%
17,219
-52,865
-75% -$308K

Similar funds

PharVision Advisers's Q1 2026 Portfolio in Review

As of Q1 2026, PharVision Advisers held 708 positions worth $9.86M, down 95% from $198M the previous quarter. Its ten largest holdings account for 18% of the portfolio.

PharVision Advisers withdrew a net $186M in Q1 2026, closing 611 positions and reducing 51 holdings. Its most notable exit was EXL Service, an estimated $830K position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.

Against the trend, PharVision Advisers opened a new position in ACV Auctions worth $125K.

  • PharVision Advisers's largest Q1 2026 buy was ACV Auctions: 29,579 shares worth $125K.
  • PharVision Advisers added most to Embecta in Q1 2026, an estimated $48.4K increase.
  • PharVision Advisers's biggest Q1 2026 reduction was Herbalife, cutting an estimated $621K.
  • PharVision Advisers fully exited EXL Service in Q1 2026, selling an estimated $830K.
  • PharVision Advisers's ten largest holdings make up 18% of its $9.86M portfolio in Q1 2026.
  • PharVision Advisers opened 41 new positions and closed 611 in Q1 2026.
  • PharVision Advisers's portfolio value fell 95% quarter-over-quarter to $9.86M.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.